title: Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
abstract: This study assessed the relevance of 2013 European LeukaemiaNet (ELN) response categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia in chronic phase (CML-CP). Four hundred and eighty-seven patients treated with imatinib (400 mg; IM 400, n = 70; 800 mg; IM800, n = 201), dasatinib (n = 107) or nilotinib (n = 109) were analysed. Intention to treat (ITT) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3 months, 78%, 17% and 6% at 6 months, and 75%, 13% and 13% at 12 months, respectively. Rates of optimal response at 3 months were 75% for IM400, 90% for IM800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6 months; and 47%, 77%, 76% and 87% at 12 months, respectively. Patients achieving optimal response had longer eventfree (EFS), failurefree (FFS), transformationfree (TFS) and overall survival (OS) compared to warning and failure responses at all-time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS, FFS, TFS and OS at 3, 6 and 12 months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKIs.
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.|Department of Internal Medicine, Utah, USA.
authors: Preetesh
authors: P
authors: Jain
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Hagop
authors: H
authors: Kantarjian
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Koji
authors: K
authors: Sasaki
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Elias
authors: E
authors: Jabbour
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Jyothsna
authors: J
authors: Dasarathula
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.|Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Graciela
authors: G
authors: Nogueras Gonzalez
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Srdan
authors: S
authors: Verstovsek
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Gautam
authors: G
authors: Borthakur
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: William
authors: W
authors: Wierda
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Tapan
authors: T
authors: Kadia
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Sara
authors: S
authors: Dellasala
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Sherry
authors: S
authors: Pierce
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Farhad
authors: F
authors: Ravandi
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Susan
authors: S
authors: O'Brien
authors: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors: Jorge
authors: J
authors: Cortes
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D015996:Survival Rate; D013997:Time Factors
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib
keywords: ELN; European LeukaemiaNet; chronic myeloid leukaemia; response in CML; tyrosine kinase inhibitor (TKI)